The role of the U.S. Food and Drug Administration in device evaluation and monitoring - 24/08/11
ASGE Technology Committee
David L. Diehl, MD, William M. Tierney, MD : Committee Chair, Douglas G. Adler, MD, Jason D. Conway, MD, MPH, Francis A. Farraye, MD, MSc, Sergey V. Kantsevoy, MD, PhD, Vivek Kaul, MD, Sripathi R. Kethu, MD, Richard S. Kwon, MD, Petar Mamula, MD : NASPGHAN representative, Marcos C. Pedrosa, MD, Sarah A. Rodriguez, MDRiassunto |
The American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee provides reviews of existing, new, or emerging endoscopic technologies that have an impact on the practice of GI endoscopy. Evidence-based methodology is used by performing a MEDLINE literature search to identify pertinent clinical studies on the topic and a MAUDE (U.S. Food and Drug Administration Center for Devices and Radiological Health) database search to identify the reported complications of a given technology. Both are supplemented by accessing the “related articles” feature of PubMed and by scrutinizing pertinent references cited by the identified studies.
Technology Status Evaluation Reports are drafted by 1 or 2 members of the ASGE Technology Committee, reviewed and edited by the committee as a whole, and approved by the Governing Board of the ASGE. When financial guidance is indicated, the most recent coding data and list prices at the time of publication are provided. For this review, the MEDLINE database was searched through October 2009 for articles and references related to devices and the U.S. Food and Drug Administration by using the keywords “FDA” and “devices.” In addition, the Web was searched using the same keywords. The U.S. Food and Drug Administration website was also thoroughly reviewed. Practitioners should continue to monitor the medical literature for subsequent data about these issues.
Technology Status Evaluation Reports are scientific reviews provided solely for educational and informational purposes. Technology Status Evaluation Reports are not rules and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment or payment for such treatment.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : CDRH, FDA, GMPs, IDE, MDR, PMA
Mappa
| This document is a product of the ASGE Technology Assessment Committee. This document was reviewed and approved by the governing board of the ASGE. |
Vol 72 - N° 1
P. 5-10 - luglio 2010 Ritorno al numero
Articolo precedente
- Interventional EUS
- ASGE Technology Committee, Vivek Kaul, Douglas G. Adler, Jason D. Conway, Francis A. Farraye, Sergey V. Kantsevoy, Sripathi R. Kethu, Richard S. Kwon, Petar Mamula, Marcos C. Pedrosa, Sarah A. Rodriguez, William M. Tierney
- In Memoriam—Eddy Davis Palmer
- H. Worth Boyce
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?